GLP-1 Clinical Relevance #42Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical TrialObservational StudyPediatric ObesityInsulin ResistanceEndocrinologyChildren and AdolescentsCardiovascular RiskPancreatic Fat AccumulationMetabolic DysfunctionEctopic Fat DepositionInsulin SecretionCardiometabolic Health...
GLP-1 Cardiovascular Outcomes: Metabolic Health Phenotypes
GLP-1 Clinical Relevance #45Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical ReviewObservational StudyCentral ObesityInsulin ResistanceCardiologyAdults with ObesityCardiovascular OutcomesMetabolic DysfunctionMetabolic Health PhenotypesCardiovascular Disease...
GLP-1 Receptor Agonist Safety in Women’s Hormonal Health
GLP-1 Clinical Relevance #41Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical CommentaryObservational StudyPolycystic Ovary SyndromeGLP-1 Receptor AgonistEndocrinologyWomen with PCOSInsulin Resistance ReductionIncretin EffectWomen’s Health SafetyHormonal ConditionsReproductive...
GLP-1 Receptor Agonist Clinical Evidence on Optimal Body Fat
GLP-1 Clinical Relevance #44Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical CommentaryObservational StudyMetabolic HealthInsulin ResistanceEndocrinologyAdults with ObesityBody Composition OutcomesFat Distribution PathwaysLow Body Fat RiskVisceral FatMetabolic...
GLP-1 Weight Loss Cardiovascular Evidence in Women’s Health
GLP-1 Clinical Relevance #28Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical CommentaryObservational StudyMASLDGLP-1 Receptor AgonistEndocrinologyWomen with PCOSLiver Disease ProgressionHormonal Metabolic PathwaysPolycystic Ovary SyndromePregnancy OutcomesMetabolic DysfunctionSex-Specific...
Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration.
Cannabidiol (CBD) and cannabigerol (CBG) are non-psychoactive phytocannabinoids with emerging therapeutic potential in metabolic dysfunction-associated steat…